State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200032, China.
Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11.
Chimeric antigen receptors (CARs) are artificial recombinant receptors that generally combine the antigen-recognition domain of a monoclonal antibody with T cell activation domains. Recent years have seen great success in clinical trials employing CD19-specific CAR-T cell therapy for B cell leukemia. Nevertheless, solid tumors remain a major challenge for CAR-T cell therapy. This review summarizes the preclinical and clinical studies on the treatment of solid tumors with CAR-T cells. The major hurdles for the success of CAR-T and the novel strategies to address these hurdles have also been described and discussed.
嵌合抗原受体 (CARs) 是一种人工重组受体，通常将单克隆抗体的抗原识别结构域与 T 细胞激活结构域结合在一起。近年来，采用 CD19 特异性 CAR-T 细胞疗法治疗 B 细胞白血病的临床试验取得了巨大成功。然而，实体瘤仍然是 CAR-T 细胞治疗的主要挑战。本文综述了 CAR-T 细胞治疗实体瘤的临床前和临床研究。还描述和讨论了 CAR-T 成功的主要障碍以及解决这些障碍的新策略。
